|
CA1172255A
(fr)
*
|
1980-12-11 |
1984-08-07 |
Robert R. Covington |
Methode de preparation de buspirone
|
|
JPH0635450B2
(ja)
*
|
1984-03-16 |
1994-05-11 |
三井東圧化学株式会社 |
チオシアノピリミジン誘導体、その製造法および農園芸用殺菌剤
|
|
US5658923A
(en)
*
|
1992-09-18 |
1997-08-19 |
Asahi Kasei Kogyo Kabushiki Kaisha |
Azepine derivatives and use thereof
|
|
EP0661271B1
(fr)
*
|
1992-09-18 |
2000-04-26 |
Asahi Kasei Kogyo Kabushiki Kaisha |
Derives d'azepine, leur production et utilisation comme ligands du recepteur sigma
|
|
CA2208900C
(fr)
*
|
1996-07-18 |
2006-08-01 |
Lonza Ag |
Methode de preparation de pyrimidine-2-carboxylates
|
|
BR9908004A
(pt)
|
1998-02-17 |
2001-12-18 |
Tularik Inc |
Composto, composição e método para prevençãoou supressão de uma infecção viral
|
|
US6410726B1
(en)
|
2000-01-12 |
2002-06-25 |
Tularik Inc. |
Arylsulfonic acid salts of pyrimidine-based antiviral
|
|
US7423148B2
(en)
*
|
2002-11-21 |
2008-09-09 |
Chiron Corporation |
Small molecule PI 3-kinase inhibitors and methods of their use
|
|
MXPA05007485A
(es)
*
|
2003-01-14 |
2006-01-30 |
Arena Pharm Inc |
Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
|
|
SI1599468T1
(sl)
*
|
2003-01-14 |
2008-02-29 |
Arena Pharm Inc |
1,2,3-trisubstituirani arilni in heteroarilni derivati kot modulatorji metabolizma ter profilaksa in zdravljenje motenj v zvezi z njim, kot diabetesain hiperglikemije
|
|
EP1638955A2
(fr)
*
|
2003-07-02 |
2006-03-29 |
Vertex Pharmaceuticals Incorporated |
Pyrimidines utilisees comme modulateurs des canaux ioniques sensibles au voltage
|
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
|
EP1648874B1
(fr)
|
2003-07-30 |
2011-10-05 |
Xenon Pharmaceuticals Inc. |
Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
|
|
CN1829701A
(zh)
|
2003-07-30 |
2006-09-06 |
泽农医药公司 |
哌嗪衍生物和它们作为治疗剂的用途
|
|
HUP0400405A3
(en)
*
|
2004-02-10 |
2009-03-30 |
Sanofi Synthelabo |
Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
|
|
JP2007217282A
(ja)
*
|
2004-03-04 |
2007-08-30 |
Astellas Pharma Inc |
置換ピリミジン誘導体
|
|
CA2580762A1
(fr)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Derives heterocycliques et leur utilisation comme agents therapeutiques
|
|
US7829712B2
(en)
|
2004-09-20 |
2010-11-09 |
Xenon Pharmaceuticals Inc. |
Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
|
|
EP2289510A1
(fr)
|
2004-09-20 |
2011-03-02 |
Xenon Pharmaceuticals Inc. |
Dérivés hétérocycliques pour le traitement des maladies induites par des enzymes stearoyl-coa desaturase
|
|
AU2005286648A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
|
|
AR051091A1
(es)
|
2004-09-20 |
2006-12-20 |
Xenon Pharmaceuticals Inc |
Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
|
|
CA2580857A1
(fr)
|
2004-09-20 |
2006-09-28 |
Xenon Pharmaceuticals Inc. |
Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
|
|
EP1807085B1
(fr)
|
2004-09-20 |
2013-08-21 |
Xenon Pharmaceuticals Inc. |
Dérivés hétérocycliques et leur utilisation en tant qu'agents thérapeutiques
|
|
MY148521A
(en)
|
2005-01-10 |
2013-04-30 |
Arena Pharm Inc |
Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
|
|
DOP2006000010A
(es)
|
2005-01-10 |
2006-07-31 |
Arena Pharm Inc |
Procedimiento para preparar eteres aromáticos
|
|
WO2006130493A2
(fr)
|
2005-05-31 |
2006-12-07 |
Vertex Pharmaceuticals Incorporated |
Heterocycles utiles comme modulateurs de canaux ioniques
|
|
AU2006343359A1
(en)
|
2005-06-03 |
2007-11-15 |
Xenon Pharmaceuticals Inc. |
Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
|
|
GB0512844D0
(en)
*
|
2005-06-23 |
2005-08-03 |
Novartis Ag |
Organic compounds
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
WO2008098058A1
(fr)
|
2007-02-06 |
2008-08-14 |
Novartis Ag |
Inhibiteurs de la pi3-kinase et procédés de leur utilisation
|
|
RU2443699C2
(ru)
|
2007-09-20 |
2012-02-27 |
Айрм Ллк |
Соединения и композиции в качестве модуляторов активности gpr119
|
|
CN102046609B
(zh)
*
|
2008-03-31 |
2014-05-14 |
全药工业株式会社 |
具有细胞保护效果的嘧啶衍生物及其应用
|
|
ES2467108T3
(es)
*
|
2008-12-09 |
2014-06-11 |
Gilead Sciences, Inc. |
Moduladores de receptores tipo toll
|
|
PH12013500547A1
(en)
|
2010-09-22 |
2013-06-10 |
Arena Pharm Inc |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
KR20140069235A
(ko)
|
2011-09-27 |
2014-06-09 |
노파르티스 아게 |
돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
|
|
CN103204816B
(zh)
|
2012-01-16 |
2016-04-27 |
中国人民解放军军事医学科学院毒物药物研究所 |
哌嗪基嘧啶类衍生物及其制备方法和用途
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
EP2970240B1
(fr)
|
2013-03-14 |
2018-01-10 |
Novartis AG |
3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
|
|
MX386419B
(es)
|
2015-01-06 |
2025-03-18 |
Arena Pharm Inc |
Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
|
|
EP3939965A1
(fr)
|
2015-06-22 |
2022-01-19 |
Arena Pharmaceuticals, Inc. |
Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique pour une utilisation dans des troubles associés au récepteur de s1p1
|
|
MA47504A
(fr)
|
2017-02-16 |
2019-12-25 |
Arena Pharm Inc |
Composés et méthodes de traitement de l'angiocholite biliaire primitive
|
|
ES2987794T3
(es)
|
2018-06-06 |
2024-11-18 |
Arena Pharm Inc |
Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
|